According to the bulk deal data of the bourses, Janus Overseas Fund sold 7.19 lakh shares of Strides Arcolab on the BSE. It sold 5.12 lakh shares of the company on the NSE.
The shares were offloaded at an average price of Rs 546 apiece, valuing the transactions at Rs 67.2 crore.
In an separate bulk deal, another Strides Arcolab shareholder Morgan Stanley Asia (Singapore) today picked up 10.55 lakh shares of the drug firm for Rs 57.73 crore.
As on quarter ending March 2013, Janus Overseas Fund shareholding amounted to 2.99 per cent in Strides Arcolab, while Morgan Stanley Asia (Singapore) held 6.66 per cent stake in the company.
For the same quarter, Macquaire Bank held 2.82 per cent stake in Strides Arcolab.
Last week, Strides Arcolab manufacturing facility at Bangalore had been approved by the US health regulator after a successful audit of the plant.
The KRS Gardens facility in Bangalore manufactures oral dosage forms such as tablets, capsules (both hard gelatine and soft gelatine) and sachets.
Shares of Strides Arcolab today gained 3.37 per cent to end the day at 544.45 apiece, on the BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
